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Combination chemotherapy used to treat patients with aggressive non-Hodgkin’s lymphoma is associated with neutropenia and
subsequent infection, hospital admission and treatment delays. Haematopoietic growth factors (HGF) can prevent neutropenia and
improve quality of life. We undertook a meta-analysis of six randomised and one nonrandomised trials to quantify the effect in
previously untreated patients, and a simple cost-effectiveness analysis. The trials compared HGF plus chemotherapy with
chemotherapy alone. In total, there were 779 patients aged between 15 and 82 years. Haematopoietic growth factors was associated
with a statistically significant 44% reduction in the incidence of severe neutropenia (neutrophil count o0.5 10
9l
 1), a 60%
reduction in the number of hospital admissions due to infection, an 80% reduction in the number of patients who had a treatment
delay due to neutropenia and a 50% reduction in hospital stay. These data together with UK G-CSF drug costs were combined to
develop a simple cost-effectiveness model, based on direct costs. Given the current cost of G-CSF, it would only be cost-effective
among patients in which high rates of hospital stay due to neutropenia or infection are expected. Alternatively, if the cost could be
reduced then all patients may be able to obtain the benefits. However, the evidence that prophylactic HGFs are clinically worthwhile
is clear.
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BACKGROUND
Intensive chemotherapy can be highly effective in the treatment of
aggressive non-Hodgkin’s lymphoma (NHL). However, this form
of treatment is associated with neutropenia that can result in
infection and subsequent hospital admission, treatment delays and
chemotherapy dose reduction. Haematopoietic growth factors
(HGF) can be used to prevent neutropenia and its consequences in
untreated patients with advanced NHL. We here present a meta-
analysis based on the controlled trials of the clinical effectiveness
of such growth factors, when used as a primary prophylaxis. We
also present a simple cost-effectiveness analysis.
PATIENTS AND METHODS
Clinical effectiveness
A systematic review of the literature was performed to identify
clinical trials that compared HGF plus chemotherapy with
chemotherapy alone. The literature search covered several medical
databases; Medline, Embase, Cancerlit, Cochrane library, the
UICCR Trials Register and the publication databases of the
European Haematology Association and the American Society of
Hematology. Keywords used were ‘lymphoma’, ‘growth factors’,
‘G-CSF or GM-CSF’ and ‘trial’.
The analyses presented here were based on the six randomised
controlled trials (Pettengell et al, 1992; Gerhartz et al, 1993; Aviles
et al, 1994; Fridik et al, 1997; Gisselbrecht et al, 1997; Zinzani et al,
1997) and one nonrandomised trial (Bertini et al, 1996), which
assessed the use of HGF in patients with aggressive NHL who had
not been treated previously. All but one trial used granulocyte
colony-stimulating factor (G-CSF), the other trial used granulo-
cyte-macrophage-CSF (GM-CSF) (Gerhartz et al, 1993). The dose
was specified as 5mgkgday
 1 in five trials (Aviles et al, 1994;
Bertini et al, 1996; Fridik et al, 1997; Gisselbrecht et al, 1997;
Zinzani et al, 1997), 5.6mgkgday
 1 in one trial (Gerhartz et al,
1993) and 230mgm
 2 in another trial (Pettengell et al, 1992).
Information on the following outcomes were obtained for each
treatment group from each published report, where available:
  the incidence of severe neutropenia (neutrophil count
o0.5 10
9l
 1)
  the incidence of severe or clinically important infections. The
definition of this varied between the trials and are given in the
Footnote to Table 2.
  the proportion of patients admitted to hospital
  the average length of stay in hospital
  the proportion of patients who had their chemotherapy
treatment delayed
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l  the proportion of patients with complete (or complete/partial)
tumour remission
  the proportion of patients surviving to 2, 2.5 or 5 years
For each outcome and trial, the relative risk and 95% confidence
interval (CI) was calculated by comparing the proportion (or
incidence) in the G-CSF group with the proportion (or incidence)
in the control (no G-CSF) group. A statistical test for heterogeneity
was performed for each outcome to assess whether the relative
risks were significantly different between the trials (Whitehead and
Whitehead, 1991). In the absence of statistically significant
heterogeneity, indicating consistency between the trial results,
the pooled relative risk was obtained by taking an average of the
log relative risks each weighted by its standard error (Whitehead
and Whitehead, 1991).
Cost-effectiveness
A measure of financial cost was taken as the cost of hospitalisation
per patient associated with a febrile neutropenic event. A
sensitivity analysis was based on varying (i) the percentage of
patients who, if not given HGF, would be hospitalised (this is the
same as the chance of a single patient being hospitalised) and (ii)
the number of times each patient could be hospitalised during five
treatment cycles (the number of cycles can vary in practice, usually
from 4 to 6, so we reported results for five cycles). We estimated
the percentage reduction in the published list price of G-CSF that
would be needed in order for the health service cost to be cheaper
than if it were not used. The analysis was also performed assuming
that the dose of G-CSF could be reduced from the standard dose of
5t o2mgkgday
 1 (a clinical trial has suggested that the lower dose
has a similar effect on neutropenia as the standard dose (Toner
et al, 1998)).
Two results from the meta-analysis of the clinical outcomes were
used:
  The reduction in hospital admission due to infection
  The reduction in length of stay
The cost parameters were as follows:
  The cost of G-CSF per patient was taken as d4406 (using a
typical list price of d3750, assuming d75 (British National
Formulation, 2002) per day over 10 days in each of the five
treatment cycles and increased by 17.5%, Value Added Tax).
  The cost of hospitalisation for a patient with a neutropenic
event was taken as d2750; estimated using the figure of d2290
(1996 costs, Office of Health Economics, 1998) and increased by
3% per year to possibly reflect current costs (in 2002) after
inflation.
  The cost of chemotherapy was not included since this will
be the same regardless of whether the patient received G-CSF
or not.
The cost per patient not given G-CSF is estimated as the
percentage of patients hospitalised cost of hospitalisa-
tion number of cycles each patient is admitted for. The cost
per patient given G-CSF is estimated by the same formula but the
percentage of patients hospitalised is reduced by the relative risk
associated with hospitalisation and the reduction in the length of
stay (obtained from the meta-analysis of the clinical trials) and the
cost of G-CSF is added.
RESULTS
Clinical effectiveness
Table 1 shows information about the trials, namely country of
origin, age range of the patients, the chemotherapy treatment
administered and the number of patients in each treatment arm.
Table 2 shows the relative risk associated with neutropenia,
clinically relevant infection (defined in various ways, see footnote
to table), hospitalisation and treatment delays and the ratio of the
mean hospital stay in the G-CSF (or GM-CSF) group compared to
those not given growth factors. There was no evidence of
heterogeneity in relation to any of the outcomes (P40.16).
G-CSF was associated with a statistically significant
44% reduction in the incidence of severe neutropenia (relative
risk 0.56, Po0.001) and a 43% reduction in the number of patients
with a clinically relevant infection (relative risk 0.57, Po0.001).
As a consequence, there was a 60% reduction in the number of
hospital admissions due to infection (relative risk 0.40, P¼0.006)
and if a patient on G-CSF were admitted they spent about half the
time in hospital (ratio of the mean hospital stay 0.53). Adminis-
tering G-CSF also had an effect on patients experiencing a
treatment delay; there was a 60% reduction in the number of
patients experiencing a treatment delay for any reason (relative
risk 0.40, Po0.001) and an 80% reduction in the number of
patients whose delay was due to neutropenia (relative risk 0.20,
Po0.001).
Table 3 shows the results in relation to tumour remission
and survival. There was no heterogeneity between the trials
reporting on complete remission (P¼0.90), those reporting on
complete or partial remission combined (P¼0.99) or those
reporting on survival (P40.90). There was no evidence that the
use of G-CSF influenced tumour remission or survival; the pooled
relative risks were close to unity and none were statistically
significant.
Table 1 General information on the controlled trials of G-CSF in patients with high-grade non-Hodgkin’s lymphoma
Trial reference
a Country
Age range of patients,
years (mean age) Chemotherapy
Number of patients
given G-CSF
b
Number of patients
not given G-CSF
Pettengell et al (1992) UK 16–71 (52) VAPEC-B
c 41 39
Gerhartz et al (1993)
b Germany 15–73 (50) COP-BLAM
d 87 85
Aviles et al (1994) Mexico 18–65 (51) ESAP, m-BECOD, MVPP-Bleo
e 20 22
Bertini et al (1996) Italy 65–80 (71) P-VEBEC
f 46 54
Fridik et al (1997) Austria 18–75 (52) CEOP/IMVP-Dexa
g 38 36
Gisselbrecht et al (1997) France 16–55 (38) LNH-84
h 82 80
Zinzani et al (1997) Italy 60–82 (69) VNCOP-B
i 77 72
aAll were randomised except Bertini et al (1996).
bThe trial by Gerhartz et al (1993) used GM-CSF.
cVAPEC-B (vincristine, adriamycin, prednisolone, etoposide,
cyclophosphamide, bleomycin).
dCOP-BLAM (cyclophosphamide, vincristine, prednisolone, bleomycin, doxorubicin, procarbazine).
eESAP (etoposide, Solu-Medrol, cytosine
arabinoside, cis-platinum); m-BECOD (methotrexate, bleomycin, epirubicin, cyclophosphamide, vincristine, dexamethasone).
fP-VEBEC (epirubicin, cyclophosphamide,
etoposide, vinblastine, bleomycin, prednisone).
gCEOP/IMVP-Dexa (cyclophosphamide, epirubicin, vincristine, prednisolone, ifosfamide, methotrexate, VP-16, dexamethasone).
hLNH (cyclophosphamide, vindesine, bleomycin, prednisone, methotrexate and either adriamycin or mitoxantrone).
iVNCOP-B (cyclophosphamide, mitoxantrone, vincristine,
etoposide, bleomycin, prednisone).
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From the section above, in patients given G-CSF compared
to those who were not, the relative risk for hospital admission
due to infection was 0.4 and the ratio for the length of stay was
0.53. These estimates are used in the following cost-effectiveness
analysis.
Table 4 shows the reduction in the list price of G-CSF needed
such that the health service cost becomes cheaper if it
were routinely used as a primary prophylaxis than if it were not
used. A relatively large proportion of patients need to be admitted
several times in the absence of using G-CSF before a policy of
offering it routinely becomes cost-effective. The percentage
of patients in the control group that required hospitalisation
due to infection was 7% in one trial (Zinzani et al, 1997) and 31%
in another (Gerhartz et al, 1993). In the UK, it is about 15%
after first-line therapy and 30% after second- or third-line therapy.
With these estimates, the published list price of G-CSF would
have to be reduced significantly for it to be worthwhile.
For example, if 15% of patients were each hospitalised twice
during their course of treatment, G-CSF would have to be
purchased at a cost that is 85% lower than the list price for it to
be cost-effective, that is d660 compared to d4406. The required
reduction in the list price is less if the dose of G-CSF can be
reduced to 2mgkgday
 1 (63%). Similarly, the higher the chance of
an individual patient being hospitalised the less the reduction in
the list price of G-CSF.
DISCUSSION
The results of the meta-analyses show that the use of HGFs
such as G-CSF has a significant effect on several important
clinical outcomes associated with the management of patients
with aggressive NHL. They result in far fewer patients
with neutropenia and as a consequence fewer patients with
infection, fewer who are hospitalised due to infection and fewer
whose chemotherapy treatment has to be delayed. There was
however no evidence of an improvement on tumour remission or
survival.
Our simple cost-effectiveness analysis, based on direct costs
alone, suggests that using G-CSF as a primary prophylaxis for
Table 2 The relative risk (or ratio) in relation to specified outcomes, comparing the rate in the G-CSF group with the rate in the non-G-CSF group
Relative risk and 95% confidence interval
Severe
neutropenia
a
Severe or clinically
important infection
b
Hospitalisation
c Treatment delays
Trial reference
All delays
d Delays due to
neutropenia
Mean hospital
stay (ratio)
e
Pettengell et al (1992) 0.44 (0.23–0.85) 0.63 (0.26–1.55) 0.95 (0.51–1.77) 0.48 (0.22–1.02) 0.10 (0.02–0.43) 0.44 (P¼0.01)
Gerhartz et al (1993) 0.73 (0.44–1.21) 0.45 (0.23–0.89) 0.35 (0.17–0.69) 0.19 (Po0.001)
Aviles et al (1994) 0.17 (0.07–0.37) 0.11 (0.05–0.23) 0.75 (P40.05)
Bertini et al (1996) 0.47 (0.23–0.98) 0.47 (0.09–2.42) 0.53 (Po0.05)
Fridik et al (1997) 0.68 (0.21–2.13)
Gisselbrecht et al (1997) 0.70 (0.47–1.03) 0.50 (0.31–0.81) 0.24 (0.11–0.56)
Zinzani et al (1997) 0.42 (0.24–0.73) 0.25 (0.08–0.75) 0.09 (0–0.99)
All trials 0.56 (0.42–0.74)
f 0.57 (0.42–0.77)
f,g 0.40 (0.21–0.77)
c 0.40 (0.24–0.69) 0.20 (0.10–0.41)
g 0.53
0.54 (0.41–0.71)
h 0.57 (0.42–0.76)
h,g 0.55 (0.26–1.18)
c
aAbsolute neutrophil count o0.5 10
9l
 1.
bDefined as – ANCo0.5 10
9l
 1 and fever X37.51C (Pettengell); severity score 2–4 (Gerhartz et al, 1993); not specified (Aviles
et al, 1994); Xgrade 3 (Bertini et al, 1996); described as ‘documented infection’ (Fridik et al, 1997); Xgrade 2 (Gisselbrecht et al, 1997); described as ‘clinically relevant’ (Zinzani
et al, 1997).
cBased on admissions due to infection except Pettengell et al (1992) in which all admissions were included. The pooled relative risk of 0.40 excludes the trial by
Pettengell et al (1992) and the one of 0.55 includes this trial.
dX8 days (Pettengell et al, 1992) or X10 days (Gerhartz et al 1993).
eThe ratio of the mean number of days in
hospital in the G-CSF group to the mean in the non-G-CSF group. The P-values were those reported in the publication based on comparing G-CSF with the non-G-CSF group.
The pooled ratio is a weighted average of the individual ratios, weighted by the total number of patients in each trial.
fExcluding the nonrandomised trial by Bertini et al (1996).
gExcluding the trial by Aviles et al (1994) because the results were based on number of cycles, not patients.
hIncluding the nonrandomised trial by Bertini et al (1996).
Table 3 The relative risk of having a complete/partial tumour remission or surviving to 2 or more years in the G-CSF group compared to the non-G-CSF
group
Relative risk and 95% confidence interval
Trial reference Complete remission Complete or partial remission Survival
Pettengell et al (1992) 0.98 (0.62–1.55) 1.07 (0.62–1.85), 2 years
Gerhartz et al (1993) 1.23 (0.79–1.93) 1.03 (0.74–1.43)
Aviles et al (1994) 1.47 (0.69–3.10)
Bertini et al (1996) 0.91 (0.55–1.50)
Fridik et al (1997) 1.14 (0.67–1.97) 1.16 (0.66–2.04), 5 years
Gisselbrecht et al (1997) 0.92 (0.64–1.34) 0.99 (0.71–1.38) 1.15 (0.77–1.72), 5 years
Zinzani et al (1997) 1.02 (0.67–1.56) 1.02 (0.68–1.53), 2.5 years
All trials 1.07 (0.87–1.32)
a 1.00 (0.81–1.24) 1.15 (0.83–1.60), 5 years
1.05 (0.87–1.27)
b 1.04 (0.75–1.44), 2 or 2.5 years
aExcluding the nonrandomised trial by Bertini et al (1996).
bIncluding the nonrandomised trial by Bertini et al (1996).
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the service provider than not using it, a similar conclusion found
by others in Canada and Italy (Zagonel et al, 1994, Dranitsaris et al,
1997). However, the analysis will to some extent underestimate
the cost-effectiveness of using G-CSF because we only included
hospital admissions due to febrile neutropenic events but there
will be patients with infection who require treatment that
are not hospitalised and we did not include the cost of having
a treatment delay due to neutropenia. When indirect costs
have been included in other cost-effectiveness analyses, for
example loss of earnings in patients unable to work because
of a neutropenic event, it has been concluded that HGFs can be
cost-effective (Dranitsaris et al, 1997). The inclusion or exclusion
of such indirect costs in patients with haematological malignancies
needs further consideration together with the quality of life
benefits, as recommended by the 1998 Office of Health Economics
report on NHL.
The evidence shows that the routine use of HGFs is worthwhile.
Although they may seem to be expensive to the health service, it
would be unsatisfactory to choose financial saving over patient
health.
In 1999, there were 9014 new cases of NHL in the UK (ONS,
2001) and it is estimated that the incidence is rising by about 4%
per annum (Office of Health Economics, 1998). As a consequence,
the number of patients with high-grade NHL is likely to increase.
Currently, HGFs are not administered routinely to such patients,
although it is possible that patients with mild neutropenic fever
could be managed at home with oral antibiotics. Using HGFs is
clearly clinically worthwhile but the costs need to be significantly
reduced for there to be direct financial savings to the health
service.
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